1
|
Boyd LK, Mao XY, Xue LY, et al:
High-resolution genome-wide copy-number analysis suggests a
monoclonal origin of multifocal prostate cancer. Gene Chromosomes
Cancer. 51:579–589. 2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Shimojo H, Kobayashi M, Kamigaito T,
Shimojo Y, Fukuda M and Nakayama J: Reduced glycosylation of
alpha-dystroglycans on carcinoma cells contributes to formation of
highly infiltrative histological patterns in prostate cancer.
Prostate. 71:1151–1157. 2011. View Article : Google Scholar
|
3
|
Chang HH, Chen BY, Wu CY, et al: Hedgehog
overexpression leads to the formation of prostate cancer stem cells
with metastatic property irrespective of androgen receptor
expression in the mouse model. J Biomed Sci. 18:62011. View Article : Google Scholar
|
4
|
Song LM, Zhu YC, Han P, et al: A
retrospective study: correlation of histologic inflammation in
biopsy specimens of Chinese men undergoing surgery for benign
prostatic hyperplasia with serum prostate-specific antigen.
Urology. 77:688–692. 2011. View Article : Google Scholar
|
5
|
Astigueta JC, Abad MA, Morante C, Pow-Sang
MR, Destefano V and Montes J: Characteristics of metastatic
prostate cancer ocurring in patients under 50 years of age. Actas
Urol Esp. 34:327–332. 2010.(In Spanish).
|
6
|
Lindstrom S, Schumacher FR, Cox D, et al:
Common genetic variants in prostate cancer risk prediction -
results from the NCI Breast and Prostate Cancer Cohort Consortium
(BPC3). Cancer Epidemiol Biomarkers Prev. 21:437–444. 2012.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Hall MJ, Ruth K and Giri VN: Rates and
predictors of colorectal cancer screening by race among motivated
men participating in a prostate cancer risk assessment program.
Cancer. 118:478–484. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Vindrieux D, Reveiller M, Chantepie J, et
al: Down-regulation of DcR2 sensitizes androgen-dependent prostate
cancer LNCaP cells to TRAIL-induced apoptosis. Cancer Cell Int.
11:422012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Paquet S, Fazli L, Grosse L, et al:
Differential expression of the androgen-conjugating UGT2B15 and
UGT2B17 enzymes in prostate tumor cells during cancer progression.
J Clin Endocrinol Metab. 97:E428–E432. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Armstrong AJ, Eisenberger MA, Halabi S, et
al: Biomarkers in the management and treatment of men with
metastatic castration-resistant prostate cancer. Eur Urol.
61:549–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Prensner JR, Rubin MA, Wei JT and
Chinnaiyan AM: Beyond PSA: the next generation of prostate cancer
biomarkers. Sci Transl Med. 4:127rv32012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Lattanzi J, McNeely S, Hanlon A, Das I,
Schultheiss TE and Hanks GE: Daily CT localization for correcting
portal errors in the treatment of prostate cancer. Int J Radiat
Oncol Biol Phys. 41:1079–1086. 1998. View Article : Google Scholar : PubMed/NCBI
|
13
|
van Vugt HA, Roobol MJ, Busstra M, et al:
Compliance with biopsy recommendations of a prostate cancer risk
calculator. BJU Int. 109:1480–1488. 2012.PubMed/NCBI
|
14
|
Schoder H and Larson SM: Positron emission
tomography for prostate, bladder, and renal cancer. Semin Nucl Med.
34:274–292. 2004. View Article : Google Scholar : PubMed/NCBI
|
15
|
Fukushima K, Satoh T, Baba S and Yamashita
K: alpha 1,2-Fucosylated and beta-N-acetylgalactosaminylated
prostate-specific antigen as an efficient marker of prostatic
cancer. Glycobiology. 20:452–460. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Page ST, Hirano L, Gilchriest J, et al:
Dutasteride reduces prostate size and prostate specific antigen in
older hypogonadal men with benign prostatic hyperplasia undergoing
testosterone replacement therapy. J Urol. 186:191–197. 2011.
View Article : Google Scholar
|
17
|
Luo J, Zha S, Gage WR, et al:
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate
cancer. Cancer Res. 62:2220–2226. 2002.PubMed/NCBI
|
18
|
Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX
and Yao XD: A multiplex model of combining gene-based,
protein-based, and metabolite-based with positive and negative
markers in urine for the early diagnosis of prostate cancer.
Prostate. 71:700–710. 2011. View Article : Google Scholar : PubMed/NCBI
|
19
|
Sreekumar A, Poisson LM, Rajendiran TM, et
al: Metabolomic profiles delineate potential role for sarcosine in
prostate cancer progression. Nature. 457:910–914. 2009. View Article : Google Scholar : PubMed/NCBI
|
20
|
Dahl M, Bouchelouche P, Kramer-Marek G,
Capala J, Nordling J and Bouchelouche K: Sarcosine induces increase
in HER2/neu expression in androgen-dependent prostate cancer cells.
Mol Biol Rep. 38:4237–4243. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
Sochor J, Ryvolova M, Krystofova O, et al:
Fully automated spectrometric protocols for determination of
antioxidant activity: advantages and disadvantages. Molecules.
15:8618–8640. 2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Sochor J, Salas P, Zehnalek J, et al: An
assay for spectrometric determination of antioxidant activity of a
biological extract. Listy Cukrov Reparske. 126:416–417. 2010.
|
23
|
Pohanka M, Sochor J, Ruttkay-Nedecky B, et
al: Automated assay of the potency of natural antioxidants using
pipetting robot and spectrophotometry. J Appl Biomed. 10:155–167.
2012. View Article : Google Scholar
|
24
|
Ghosh A, Wang YN, Klein E and Heston WD:
Novel role of prostate-specific membrane antigen in suppressing
prostate cancer invasiveness. Cancer Res. 65:727–731.
2005.PubMed/NCBI
|
25
|
Tai S, Sun Y, Squires JM, et al: PC3 is a
cell line characteristic of prostatic small cell carcinoma.
Prostate. 71:1668–1679. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Moolenaar SH, Poggi-Bach J, Engelke UF, et
al: Defect in dimethylglycine dehydrogenase, a new inborn error of
metabolism: NMR spectroscopy study. Clin Chem. 45:459–464.
1999.PubMed/NCBI
|
27
|
Cernei N, Zitka O, Ryvolova M, et al:
Spectrometric and electrochemical analysis of sarcosine as a
potential prostate carcinoma marker. Int J Electrochem Sci.
7:4286–4301. 2012.
|
28
|
Eckschlager T, Adam V, Hrabeta J, Figova K
and Kizek R: Metallothioneins and cancer. Curr Protein Pept Sci.
10:360–375. 2009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Krizkova S, Fabrik I, Adam V, Hrabeta J,
Eckschlager T and Kizek R: Metallothionein - a promising tool for
cancer diagnostics. Bratisl Lek Listy. 110:93–97. 2009.PubMed/NCBI
|
30
|
Krizkova S, Adam V, Eckschlager T and
Kizek R: Easy-to-use and rapid detection of potential tumour
disease marker metallothionein by using of PVDF membranes and
chicken antibodies. FEBS J. 276:317. 2009.
|
31
|
Krizkova S, Fabrik I, Huska D, et al: An
adsorptive transfer technique coupled with Brdicka reaction to
reveal the importance of metallothionein in chemotherapy with
platinum based cytostatics. Int J Mol Sci. 11:4826–4842. 2010.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Krizkova S, Masarik M, Majzlik P, et al:
Serum metallothionein in newly diagnosed patients with childhood
solid tumours. Acta Biochim Pol. 57:561–566. 2010.PubMed/NCBI
|
33
|
Krejcova L, Fabrik I, Hynek D, et al:
Metallothionein electrochemically determined using Brdicka reaction
as a promising blood marker of head and neck malignant tumours. Int
J Electrochem Sci. 7:1767–1784. 2012.
|
34
|
Sochor J, Hynek D, Krejcova L, et al:
Study of metallothionein role in spinocellular carcinoma tissues of
head and neck tumours using Brdicka reaction. Int J Electrochem
Sci. 7:2136–2152. 2012.
|
35
|
Gumulec J, Masarik M, Krizkova S, et al:
Evaluation of alpha-methylacyl-CoA racemase, metallothionein and
prostate specific antigen as prostate cancer prognostic markers.
Neoplasma. 59:191–201. 2012. View Article : Google Scholar : PubMed/NCBI
|
36
|
Krizkova S, Ryvolova M, Gumulec J, et al:
Electrophoretic fingerprint metallothionein analysis as a potential
prostate cancer biomarker. Electrophoresis. 32:1952–1961. 2011.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Hamer DH: Metallothionein. Annu Rev
Biochem. 55:913–951. 1986. View Article : Google Scholar : PubMed/NCBI
|
38
|
Krizkova S, Adam V and Kizek R: Study of
metallothionein oxidation by using of chip CE. Electrophoresis.
30:4029–4033. 2009. View Article : Google Scholar : PubMed/NCBI
|
39
|
Krizkova S, Masarik M, Eckschlager T, Adam
V and Kizek R: Effects of redox conditions and zinc(II) ions on
metallothionein aggregation revealed by chip capillary
electrophoresis. J Chromatogr A. 1217:7966–7971. 2010. View Article : Google Scholar : PubMed/NCBI
|
40
|
Adam V, Fabrik I, Eckschlager T, Stiborova
M, Trnkova L and Kizek R: Vertebrate metallothioneins as target
molecules for analytical techniques. TrAC Trends Anal Chem.
29:409–418. 2010. View Article : Google Scholar
|
41
|
Ryvolova M, Krizkova S, Adam V, et al:
Analytical methods for metallothionein detection. Curr Anal Chem.
7:243–261. 2011.
|
42
|
Sochor J, Pohanka M, Ruttkay-Nedecky B, et
al: Effect of selenium in organic and inorganic form on liver,
kidney, brain and muscle of Wistar rats. Cent Eur J Chem.
10:1442–1451. 2012. View Article : Google Scholar
|
43
|
Jurikova T, Sochor J, Rop O, et al:
Evaluation of polyphenolic profile and nutritional value of
non-traditional fruit species in the Czech Republic - a comparative
study. Molecules. 17:8968–8981. 2012. View Article : Google Scholar : PubMed/NCBI
|
44
|
Rop O, Reznicek V, Mlcek J, et al:
Antioxidant and radical oxygen species scavenging activities of 12
cultivars of blue honeysuckle fruit. Hort Sci. 38:63–70. 2011.
|
45
|
Sochor J, Babula P, Krska B, et al:
Evaluation of output signals from CoulArray detector for
determination of antioxidant capacity of apricots samples. Analysis
of Biomedical Signals and Images. Jan J, Jirik R, Kolar R, Kolarova
J, Kozumplik J and Provaznik I: Brno University of Technology VUT v
Brně Press; Brno: pp. 209–214. 2010
|
46
|
Krauth-Siegel RL and Leroux AE:
Low-molecular-mass antioxidants in parasites. Antioxid Redox
Signal. 17:583–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
47
|
Pohanka M, Karasova JZ, Musilek K, Kuca K,
Jung YS and Kassa J: Changes of rat plasma total low molecular
weight antioxidant level after tabun exposure and consequent
treatment by acetylcholinesterase reactivators. J Enzyme Inhib Med
Chem. 26:93–97. 2011. View Article : Google Scholar
|
48
|
Parejo L, Codina C, Petrakis C and Kefalas
P: Evaluation of scavenging activity assessed by
Co(II)/EDTA-induced luminol chemiluminescence and DPPH·
(2,2-diphenyl-1-picrylhydrazyl) free radical assay. J Pharmacol
Toxicol Methods. 44:507–512. 2000.PubMed/NCBI
|
49
|
Nilsson J, Pillai D, Onning G, Persson C,
Nilsson A and Akesson B: Comparison of the
2,2′-azinobis-3-ethylbenzotiazoline-6-sulfonic acid (ABTS) and
ferric reducing antioxidant power (FRAP) methods to asses the total
antioxidant capacity in extracts of fruit and vegetables. Mol Nutr
Food Res. 49:239–246. 2005.
|
50
|
Asghar MN, Khan IU, Arshad MN and Sherin
L: Evaluation of antioxidant activity using an improved DMPD
radical cation decolorization assay. Acta Chim Slov. 54:295–300.
2007.
|